Please assess the completion status of the following clinical trial:

Trial Title: Study of Pharmacokinetics and Pharmacodynamics of Artesunate in Pregnant Women in the Democratic Republic of Congo

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria for Cases:~* 2nd trimester (22-26 weeks) or 3rd trimester (32-36 weeks) of pregnancy, based on an ultrasound conducted at \<22 weeks gestation (composite of BPD, HC, AC, FL)~* Singleton pregnancy documented by ultrasound~* Parasitemic (\> 500 parasites/μl)~* Afebrile and asymptomatic~* Hematocrit ≥ 30%~* Negative HIV test result~* At least 18 years of age and less than 40 years of age~* Able to spend three days in the clinic following their laboratory screening visit and again at three months postpartum~* Willing to provide informed consent~Inclusion Criteria for Non-pregnant Controls:~* Negative urine pregnancy test~* Parasitemic (\> 500 parasites/μl)~* Afebrile and asymptomatic~* Hematocrit ≥ 30%~* Negative Determine® HIV test result~* At least 18 years of age and less than 40 years of age~* Able to spend three days in the clinic following screening~* Willing to provide informed consent~Inclusion Criteria for Internal controls:~* Negative urine pregnancy test~Exclusion Criteria for Cases:~* Parasitemia \> 300,000 parasites/μl or symptomatic malaria~* Medical contraindications to participation or medical disorders (known high blood pressure, diabetes, sickle cell disease or tuberculosis)~* Have taken artesunate or any medicine containing artesunate during the current pregnancy~* Have taken any antimalarial in the past two weeks~* Have taken any medication in the past two weeks other than antipyretics (e.g., acetyl- salicylic acid, acetaminophen), folic acid or iron~* Have a fetus with any ultrasonographically visible structural fetal abnormalities identified on entry by ultrasound~* Past or present pregnancy complications that would preclude participation in the study (gestational diabetes/diabetes, incompetent cervix, pre-eclampsia/ eclampsia, and high blood pressure)~* Between 32-36 weeks gestation and have already participated in the study at 22-26 weeks gestation~Exclusion Criteria for Non-pregnant Controls:~* Parasitemia \> 300,000 parasites/μl or have symptomatic malaria~* Medical contraindications to participation or medical disorders (known high blood pressure, diabetes, sickle cell disease or tuberculosis)~* Have taken any antimalarial in the past two weeks~* Have taken any medication in the past two weeks other than antipyretics (e.g., acetyl- salicylic acid, acetaminophen), folic acid or iron~Exclusion Criteria for Internal Controls:~* Parasitemia \> 300,000 parasites/μl or have symptomatic malaria~* Have taken antimalarial medication in the past two weeks.~* Have taken any medication in the past two weeks other than antipyretics (e.g., acetyl- salicylic acid, acetaminophen), folic acid or iron~* Pregnant

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Case (Type: EXPERIMENTAL): Cases are defined as parasitemic pregnant women during the second trimester (22-26 weeks gestation) and the third trimester (32-36 weeks gestation).
- Non-pregnant Control (Type: ACTIVE_COMPARATOR): Non-pregnant controls are defined as parasitemic non-pregnant women recruited from the same community as the cases.
- Internal Control (Type: ACTIVE_COMPARATOR): Internal controls are defined as the same women(cases)at three months postpartum.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete